 |
 |
|
| Startseite |
| Impressum |
| Datenschutz |
 | |
| Volume 38, 2 February 2007 | 2/2007 |
| SPOT ON | |
Good-bye drug safety : reorganization of the German drug regulatory office BfArM and consequences | |
| THERAPY FORM A CRITICAL VIEWPOINT | |
 |
Breast cancer: survival benefit of adjuvant trastuzumab (HERCEPTIN) questionable |
| REVIEW | |
Therapy of age-related macular degeneration (II): treatment of neovascular disease | |
| a-t READERS' QUESTIONS AND COMMENTS | |
NSAID: naproxen new standard and the economic consequences | |
| IN BRIEF | |
Rosiglitazone as first line therapy in type II diabetes mellitus? | |
| CURRENT ADR NETWORK REPORT | |
Parkinson disease: heart valve disease by dopamine agonists | |
| SIDE EFFECTS | |
Failing orgasm with anticonvulsive topiramate (TOPAMAX/-MIGRÄNE) | |
|
© arznei-telegramm 2/2007 | ||
 |  | |